Qianjiang Yongan Pharmaceutical Co., Ltd.

XSEC:002365 Stock Report

Market Cap: CN¥2.2b

Qianjiang Yongan Pharmaceutical Past Earnings Performance

Past criteria checks 0/6

Qianjiang Yongan Pharmaceutical's earnings have been declining at an average annual rate of -22.7%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been declining at an average rate of 6.1% per year.

Key information

-22.7%

Earnings growth rate

-23.1%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate-6.1%
Return on equity-0.5%
Net Margin0.4%
Next Earnings Update10 Apr 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Qianjiang Yongan Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

XSEC:002365 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2478938436
30 Jun 24820-1611440
31 Mar 24858112542
31 Dec 23973-1217542
30 Sep 231,1422526744
30 Jun 231,2148027142
31 Mar 231,36110528040
01 Jan 231,46214024740
30 Sep 221,56318714247
30 Jun 221,68017714949
31 Mar 221,66415115750
01 Jan 221,56510816453
30 Sep 211,4077323654
30 Jun 211,3045920954
31 Mar 211,26810819555
31 Dec 201,17310616847
30 Sep 201,25213414644
30 Jun 201,30715014546
31 Mar 201,3108813149
31 Dec 191,3709014054
30 Sep 191,2879613845
30 Jun 191,14310513735
31 Mar 191,05713913128
31 Dec 181,00517812624
30 Sep 181,01616414930
30 Jun 181,01116814326
31 Mar 1898215215016
31 Dec 1793313314710
30 Sep 177661321142
30 Jun 176881001050
31 Mar 1760679930
31 Dec 1654962920
30 Sep 1656750900
30 Jun 1654439940
31 Mar 1654121920
31 Dec 1555618900
30 Sep 1559819890
30 Jun 1568125810
31 Mar 1566136750
31 Dec 1465832720
30 Sep 1459429610
30 Jun 1456223610
31 Mar 1453514610

Quality Earnings: 002365 has a large one-off loss of CN¥59.0M impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: 002365's current net profit margins (0.4%) are lower than last year (2.2%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 002365's earnings have declined by 22.7% per year over the past 5 years.

Accelerating Growth: 002365's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 002365 had negative earnings growth (-87.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.5%).

Return on Equity

High ROE: 002365's Return on Equity (-0.5%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/13 07:42
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Qianjiang Yongan Pharmaceutical Co., Ltd. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Shuchang LiuChangjiang Securities Co. LTD.
Bin WuChina Merchants Securities Co. Ltd.
Peng LiuGuosen Securities Co., Ltd.